Argen-x N.v.

Argenx Bv

Argenx Bvba

Natalie De Jonge

Torsten Dreier

Johannes De Haard

Anna Hultberg

Michael Saunders

Els Festjens

Christophe Blanchetot

Paolo Michieli

Cristina Basilico

Sebastian Paul Van Der Woning

Johannes Joseph Wilhelmus De Haard

Nicolas Ongenae

Karen Silence

Peter Ulrichts

Paulo Michieli

The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer).

IL-6 binding molecules

The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.

Anti c-Met antibodies

Provided are chimeric, camelid-human (e.g., llama-human) polypeptides comprising a first antigenic polypeptide portion and a second antigenic polypeptide portion wherein the first antigenic portion is a derived from a first portion of a camelid (e.g., llama) and the second antigenic portion is a human polypeptide homolog of a second portion of the camedid antigen. The chimeric polypeptides are useful inter alia for epitope mapping and generation of antibodies that bind to a desired region of human antigen.

Chimeric human-llama antigens and methods of use

The invention provides a product combination or composition, and also multispecific antibodies comprising two or more antigen-binding sites (as antibodies or antigen binding fragments thereof), wherein two the antigen-binding bind to distinct non-overlapping epitopes of the human c-Met protein. The product combination or composition or multispecific antibody inhibits HGF-independent activation of the human c-Met receptor protein.

C-Met antibody combinations

Growing community of inventors

Aalst, Belgium

Natalie De Jonge